Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Tamer Basel ShabanehAndrew R StevensSylvia M StullKristen R ShimpBrandon W SeatonEkram A GadCarla A Jaeger-RuckstuhlSylvain SimonAmanda L KoehneJason P PriceJames M OlsonBenjamin G HoffstromDavid JellymanStanley R RiddellPublished in: Journal for immunotherapy of cancer (2024)
Our findings illustrate the disadvantage of high-affinity CARs for targets such as HER2 that are expressed on normal tissues. The use of low-affinity HER2 CARs can safely regress tumors identifying a potential path for therapy of solid tumors that exhibit high levels of HER2.